Semisynthetic protein-based site-directed probes for identification and inhibition of active sites, and methods therefor
CA 2483494 A1 · Owner: Wilkinson, Keith D. · Inventors: Kolli, Nagamalleswari; Wilkinson, Keith D.; Borodovsky, Anna
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A C-terminally modified Ubiquitin (Ub) derivative ubiquitin vinyl sulfone , (UbVS), which is specific for deubiquitinating enzymes (DUBs) was synthesized , as an active site directed probe that irreversibly modifies a subset of Ub Cterminal hydrolases (UCHs) and Ub specific processing proteases (UBPs) is , provided 125I-UbVS modifies 6 of the 17 known and putative yeast deubiquitinating enzymes, namely Yuh1p Ubp1p, Ubp2p, Ubp6p, Ubp12p and , Ubp15p. In mammalian cells a greater number of polypeptides is labeled most , of which are DUBs. An additional DUB that associates with the mammalian 26S proteasome, novel protein USP14, a mammalian homolog of yeast Ubp6p that is bound to the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 25, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 25, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 25, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.